[go: up one dir, main page]

AR046992A1 - Derivados de espiro-dihidrobenzofuranos - Google Patents

Derivados de espiro-dihidrobenzofuranos

Info

Publication number
AR046992A1
AR046992A1 ARP040104881A ARP040104881A AR046992A1 AR 046992 A1 AR046992 A1 AR 046992A1 AR P040104881 A ARP040104881 A AR P040104881A AR P040104881 A ARP040104881 A AR P040104881A AR 046992 A1 AR046992 A1 AR 046992A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
halogen
alkoxy
group
Prior art date
Application number
ARP040104881A
Other languages
English (en)
Inventor
Nafizal Hossain
Svetlana Ivanova
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046992A1 publication Critical patent/AR046992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a derivados de espiro-dihidrobenzofuranos, procesos para su preparacion, composiciones farmacéuticas que los contienen y su uso en terapia. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde m es 0, 1, 2, 3 o 4, donde cada R1 representa independientemente halogeno, ciano, hidroxilo, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, alquilsulfonilo C1-6 o sulfonamido (-SO2NH2); X representa una union o -CH2- e Y representa una union o -CH2-, siempre y cuando X e Y no representen ambos simultáneamente una union o -CH2-; n es 0, 1 o 2; donde cada R2 representa independientemente halogeno, alquilo C1-6 o haloalquilo C1-6; q es 0 o 1; p es 0 o 2; R3 representa un grupo que se selecciona entre halogeno, NR6R7, carboxilo o alquilo C1-6 donde dicho grupo alquilo C1-6 opcionalmente está sustituido por uno o más de halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi o carbamoilo; R4 representa H, alquilo C1-6, haloalquilo C1-6 o halogeno; t es 0, 1 o 2, siempre y cuando p y t no sean ambos 0; R5 representa un sistema de anillo saturado o insaturado de entre 5 y 10 miembros donde dicho sistema de anillo puede comprender por lo menos un heteroátomo en el anillo que se selecciona entre N, O y S, donde el sistema de anillo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, ciano, oxo, nitro, hidroxilo, carboxilo, - C(O)H, -NR8R9, -C(O)NR10R11, -NHC(O)R12, -NHSO2R13, -SO2NR14R15, -NHC(O)NR16R17, un grupo que se selecciona entre alquilo C1-6, alquenilo C2-6, alquenilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, haloalquilo C1-6, alquilcarbonilo C1- 6, fenilcarbonilo, cicloalquilo C3-6, fenilo y un anillo heterocíclico saturado o insaturado de 5 o 6 miembros que comprende por lo menos un heteroátomo en el anillo que se selecciona entre N, O y S, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxilo, carboxilo, alquilo C1-6, cicloalquilo C3-6, alcoxi C1-6 y alcoxicarbonilo C1-6, R6 y R7 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 y alquilcarbonilo C1-6, cada uno de los cuales puede estar sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, carbamoilo o alcoxicarbonilo C1-6, o R6 y R7 junto con el átomo de N al cual están unidos forman un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, carbamoilo o alcoxicarbonilo C1-6; R8, R9, R10, R11 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi o carbamoilo; o R10 y R11, junto con el átomo de N al cual están unidos, forman un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente por lo menos con un sustituyente que se selecciona entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R12 representa H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6 donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R13 representa un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; R14, R15, R16 y R17 representan cada uno independientemente H o un grupo que se selecciona entre alquilo C1-6 o cicloalquilo C3-6, donde cada grupo está sustituido opcionalmente con uno o más sustituyentes que se seleccionan independientemente entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; o R14 y R15, o R16 y R17 junto con el átomo de N al cual están unidos forma cada uno independientemente un anillo heterocíclico saturado de entre 4 y 7 miembros que puede estar sustituido opcionalmente por lo menos con un sustituyente que se selecciona entre halogeno, amino, hidroxilo, alcoxi C1-6, N-(C1-6 alquil)amino, N,N-di-(C1-6 alquil)amino, carboxi, o carbamoilo; o una sal o solvato de los mismos aceptables para uso farmacéutico.
ARP040104881A 2003-12-22 2004-12-22 Derivados de espiro-dihidrobenzofuranos AR046992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303541A SE0303541D0 (sv) 2003-12-22 2003-12-22 New compounds

Publications (1)

Publication Number Publication Date
AR046992A1 true AR046992A1 (es) 2006-01-04

Family

ID=30768856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104881A AR046992A1 (es) 2003-12-22 2004-12-22 Derivados de espiro-dihidrobenzofuranos

Country Status (17)

Country Link
US (2) US7524856B2 (es)
EP (1) EP1699791A1 (es)
JP (1) JP2007515476A (es)
KR (1) KR20060117343A (es)
CN (1) CN1918160A (es)
AR (1) AR046992A1 (es)
AU (1) AU2004303735B2 (es)
BR (1) BRPI0417036A (es)
CA (1) CA2548494A1 (es)
IL (1) IL175958A0 (es)
MX (1) MXPA06007025A (es)
NO (1) NO20063355L (es)
SE (1) SE0303541D0 (es)
TW (1) TW200604197A (es)
UY (1) UY28694A1 (es)
WO (1) WO2005061499A1 (es)
ZA (1) ZA200605082B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) * 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1758580A4 (en) 2004-06-24 2008-01-16 Incyte Corp N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
US20080064884A1 (en) * 2006-05-10 2008-03-13 Astrazeneca Ab Novel Process 1
CN101516863A (zh) * 2006-07-18 2009-08-26 阿斯利康(瑞典)有限公司 制备取代的2-乙酰基氨基-烷氧基苯的方法
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
EP2120935A4 (en) * 2007-02-23 2011-06-22 Astrazeneca Ab NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2009011654A1 (en) * 2007-07-17 2009-01-22 Astrazeneca Ab Process for the preparation of cyclic spiropiperidines
WO2009011655A1 (en) * 2007-07-17 2009-01-22 Astrazeneca Ab Splropiperidine compounds, a process of their preparation, pharmaceutical compositions containing them, and their use in the treatment of airway diseases, inflammatory diseases, copd or asthma
WO2009061881A1 (en) * 2007-11-07 2009-05-14 Glaxo Group Limited Spirodihydrobenzofurans as modulators of chemokine receptors
BRPI1012097A2 (pt) * 2009-06-10 2016-03-22 Sunovion Pharmaceuticals Inc antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP4276327B1 (en) 2021-02-08 2025-01-22 NSK Ltd. Reverse input blocking clutch

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4166120A (en) * 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4166119A (en) 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4263317A (en) 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
US5366986A (en) 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
DE3930262A1 (de) 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DK0828728T3 (da) 1995-05-18 2003-05-19 Altana Pharma Ag Phenyldihydrobenzofuraner
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998031364A1 (en) 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
WO1999040070A1 (en) 1998-02-04 1999-08-12 Banyu Pharmaceutical Co., Ltd. N-acyl cyclic amine derivatives
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2003514777A (ja) 1999-10-27 2003-04-22 シーオーアール セラピューティクス インコーポレイテッド フィブリノゲン依存性血小板凝集の阻害剤としてのピリジル含有スピロ環化合物
AU2001243394A1 (en) * 2000-03-02 2001-09-12 Smith Kline Beecham Corporation Compounds and methods
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
EP1558250A4 (en) 2002-10-30 2006-11-02 Merck & Co Inc GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US20070021498A1 (en) 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302755D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用

Also Published As

Publication number Publication date
EP1699791A1 (en) 2006-09-13
US20070099945A1 (en) 2007-05-03
MXPA06007025A (es) 2006-08-31
TW200604197A (en) 2006-02-01
CA2548494A1 (en) 2005-07-07
AU2004303735B2 (en) 2007-09-20
UY28694A1 (es) 2005-07-29
SE0303541D0 (sv) 2003-12-22
NO20063355L (no) 2006-09-22
ZA200605082B (en) 2007-11-28
US20090298861A1 (en) 2009-12-03
CN1918160A (zh) 2007-02-21
US7524856B2 (en) 2009-04-28
WO2005061499A1 (en) 2005-07-07
BRPI0417036A (pt) 2007-02-06
IL175958A0 (en) 2006-10-05
KR20060117343A (ko) 2006-11-16
JP2007515476A (ja) 2007-06-14
AU2004303735A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
AR046992A1 (es) Derivados de espiro-dihidrobenzofuranos
AR127309A2 (es) Derivados de piridazinona
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR047966A1 (es) Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR080189A2 (es) Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
AR060287A1 (es) Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR069691A1 (es) Derivados ciclopropilamina
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin

Legal Events

Date Code Title Description
FB Suspension of granting procedure